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Abstract
Aim: As technological interventions treating acute myocardial infarction (MI) improve, post-ischemic heart failure
increasingly threatens patient health. The aim of the current study was to test whether FADD could be a potential target of
gene therapy in the treatment of heart failure.
Methods: Cardiomyocyte-specific FADD knockout mice along with non-transgenic littermates (NLC) were subjected to
30 minutes myocardial ischemia followed by 7 days of reperfusion or 6 weeks of permanent myocardial ischemia via the
ligation of left main descending coronary artery. Cardiac function were evaluated by echocardiography and left ventricular
(LV) catheterization and cardiomyocyte death was measured by Evans blue-TTC staining, TUNEL staining, and caspase-3, -8,
and -9 activities. In vitro, H9C2 cells transfected with ether scramble siRNA or FADD siRNA were stressed with chelerythrin
for 30 min and cleaved caspase-3 was assessed.
Results: FADD expression was significantly decreased in FADD knockout mice compared to NLC. Ischemia/reperfusion (I/R)
upregulated FADD expression in NLC mice, but not in FADD knockout mice at the early time. FADD deletion significantly
attenuated I/R-induced cardiac dysfunction, decreased myocardial necrosis, and inhibited cardiomyocyte apoptosis.
Furthermore, in 6 weeks long term permanent ischemia model, FADD deletion significantly reduced the infarct size (from
41.2063.90% in NLC to 26.8364.17% in FADD deletion), attenuated myocardial remodeling, improved cardiac function and
improved survival. In vitro, FADD knockdown significantly reduced chelerythrin-induced the level of cleaved caspase-3.
Conclusion: Taken together, our results suggest FADD plays a critical role in post-ischemic heart failure. Inhibition of FADD
retards heart failure progression. Our data supports the further investigation of FADD as a potential target for genetic
manipulation in the treatment of heart failure.
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Introduction
Dramatic advances in the past 30 years have improved the
management of ischemic heart disease and acute myocardial
infarction (MI). As a result, mortality from coronary artery disease
and acute MI has declined, although congestive heart failure
(CHF) only reduced to a much lesser extent [1]. Over the last 25
years, hospitalizations with CHF as the principal or secondary
diagnosis in patients 65 years or older have actually increased by
70–100% [2]. As increased patient survival from initial MI
continues, the population now subject to MI’s clinical sequelae,
including heart failure, grows [3].
Acute MI may not necessarily result in left ventricular (LV)
dysfunction and heart failure, a process dependent upon several
factors, including myocardial stunning, hibernation, and remod-
eling, as well as neuroendocrine activation. Although the precise
cellular and molecular basis underlying complex heart failure
pathogenesis is not understood completely, involvement of
cardiomyocyte death, particularly apoptosis, is a pivotal element
[4,5].
Ubiquitously inherent within metazoan cells, apoptosis is
programmed suicide [6]. The involved death machinery may be
activated by stimuli originating outside (e.g., nutrient/oxygen/
survival factor deficiency, reactive oxygen species, stretch,
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ultraviolet radiation, drugs) or inside (e.g., cell cycle perturbations,
deoxyribonucleic acid damage) [7]. Two types of apoptosis
contribute to post-ischemic heart failure progression [8–10].
Firstly, a high-frequency fleeting burst of cell death occurs within
the first 24 hours in the infarct zone. Secondly, infrequent
myocyte apoptosis may persist for months in the remote
myocardium. Mitochondria and death receptors (DR) mediate
the two major apoptotic pathways [10]. Evidence suggests that the
DR pathway has more involvement with the remote, persistent
myocardial apoptotic subtype. Fas-associated death domain-
containing protein (FADD) is a vital mediator of the DR pathway
[11]. FADD is involved with DR signaling initiated by Fas,
TNFR-I, TRAIL receptors (or DR4/5), and DR3 [12]. FADD
contains two protein-protein interaction structures: the death
domain (DD) at the carboxy terminus and the death effector
domain (DED) at the amino terminus. The DD of FADD binds to
the corresponding domain within the intracellular tail of Fas,
whereas the DED of FADD associates with its respective domain
in procaspase-8 [13,14]. Apoptotic signaling is initiated by Fas
clustering induced by trimeric Fas ligand (FasL) engagement, a
signaling complex formation containing FasL, Fas, FADD, and
procaspase-8 [15]. Procaspase-8 aggregation within the death-
inducing signaling complex facilitates its autoproteolysis, leading to
its activation as a cysteine protease. Caspase-8 then activates
downstream caspases, leading to apoptotic cell death. Interacting
with DED, cellular FLICE-inhibitory protein (cFLIP) showed
critical role in the regulation of tumour necrosis factor mediated
apoptotic signaling pathway [16,17], while it protected against the
development of post-infarction cardiac remodeling in mice
through interrupting JNK1/2 signalling and augmenting Akt
signalling [18].
Given known the great importance of FADD signaling pathway,
we hypothesize FADD may represent a promising gene target for
therapeutic manipulation in attenuating post-ischemia heart
failure development. The aims of the current study are: (1) to
determine whether FADD deletion may promote cardiac function
recovery during the acute phase after myocardial ischemia/
reperfusion (I/R); (2) to determine whether FADD deletion may
rescue cardiomyocytes from cell death during the acute phase after
I/R; (3) to determine whether FADD deletion may delay long-
term ischemia induced heart failure; and (4) to determine whether
FADD deletion may decrease long-term myocardial ischemia
induced cardiac tissue death.
Methods
Generation of cardiomyocyte-specific FADD:GFP-
deficient mice
FADD2/2-FADD:GFP mice were obtained from Dr. Jianke
Zhang (Department of Microbiology, Thomas Jefferson Univer-
sity). FADD:GFP-deficient mice were generated as described
previously [19,20]. To generate cardiomyocyte-specific FADD-
deficient mice (FADD2/2), MHC-Cre transgenic mice were
crossed with FADD2/2-FADD:GFP mice to generate FADD2/2-
FADD:GFP-MHC-Cre mice. Since FADD2/2-FADD:GFP-
MHC-Cre mice are genetically weaker compared to wild type
(WT) C57/Bl6 mice we use FADD2/2-FADD:GFP-MHC-Cre2,
the non-transgenic littermates (NLC) mice line as the control.
Experimental Protocol
Adult male cardiomyocyte-specific FADD knockout (KO,
FADD2/2-FADD:GFP-MHC-Cre) mice along with NLC
(FADD2/2-FADD:GFP) mice were anesthetized with 2% isoflur-
ane. After exteriorizing the heart via a left thoracic incision,
myocardial ischemia was induced by placing a 6-0 silk slipknot
around the left main descending coronary artery as previously
described [21,22]. After 30 minutes of ischemia, the slipknot was
released, and the myocardium was reperfused for 3 hours (for
TUNEL and caspase activity assays), 24 hours (for echocardio-
graphic, hemodynamic, and infarct size assays) and 7 days
(echocardiographic, hemodynamic, and TUNEL assays). To
determine the long term effects of FADD deletion, a subset of
mice were subjected to permanent myocardial ischemia (MI), and
underwent echocardiographic measurement at baseline, 2, 4, and
6 weeks after MI. After 6 weeks MI, hemodynamic assays
commenced, and cardiectomies were performed for TTC staining.
For survival study, mice were followed up for 60 days after sham
or MI. All experiments were carried out according to the National
Institutes of Health Guidelines on the Use of Laboratory Animals
and all procedures were approved by the Animal Care Committee
at Thomas Jefferson University and Temple University.
Western Blotting
Heart tissue samples were homogenized in ice-cold lysis buffer.
After homogenization, the lysates were centrifuged, and superna-
tant was saved and separated by electrophoresis on SDS-PAGE
and transferred onto polyvinylidene difluoride (PVDF)-plus
membranes. After blocking buffer, the immunoblots were probed
with anti-FADD (Santa Cruz Biotechnology, CA) and anti-
GAPDH antibodies overnight at 4uC, followed by incubation
with fluorescent conjugated secondary antibodies at room
temperature for 1 hour.
Cardiac function measurement
Cardiac function was determined by echocardiography (Visual-
Sonics VeVo 770 imaging system) and by hemodynamic
measurement via LV catheterization (1.2-Fr micromanometer,
Millar Instruments, Houston, Texas) at above mentioned time
points. Both methods have been described in detail in our previous
publications [21,23,24].
Cardiomyocyte death (infarct size and apoptotic ratio)
Infarct size determination. Infarct size was determined by
Evans blue-TTC staining after I/R as previously described
[21,22,25]. In brief, after I/R, the ligature around the coronary
artery was retied and 0.05 ml of 1% Evans blue dye was injected
into the left coronary artery (LCA). The heart was quickly excised
and frozen for 1 hour at280uC. Each heart was then sectioned into
1.0 mm portions, and incubated at 37uC in 1% TTC-PBS for
15 minutes. Each stained cardiac section was photographed and
analyzed using the computer-based image analyzer SigmaScan Pro
5.0 (SPSS Science, Chicago, IL). The areas were defined as follows:
the infarct area (Inf) consists of the TTC-negative staining region,
the area at risk (AAR) consists of the Evan’s Blue negatively staining
region – including the TTC-positive staining and TTC-negative
staining regions, and the area not at risk (ANAR) or non-ischemic
region consists of the Evan’s blue positively staining regions.
Myocardial infarct size was calculated as a percentage of the AAR
(Inf/AAR) and the AAR was calculated as the percentage of total
LV (AAR/(AAR+ANAR)). In long term ofMI study, the infarct size
was expressed as the length of the scare/LV circumference6100.
TUNEL staining. Hearts were perfused with 0.1 ml PBS via
LCA and then dissected and fixed in 4% paraformaldehyde in PBS
(pH 7.4) for 24 hours at room temperature. Fixed tissues were
embedded in paraffin. Five sections of 6 mm thickness were cut from
each tissue block. TUNEL staining was performed per manufac-
turer’s instructions (In Situ Cell Death Protection Kit, Fluorescein,
Roche, Indianapolis, IN). Total nuclei were stained by DAPI
FADD2/2 Protects against Heart Failure
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(Vector Laboratories Inc., Burlingame, CA). Additionally, cardiac
tissue was specifically labeled by a-actinin antibody. Apoptotic
index (i.e., the number of positively stained nuclei/total number of
nuclei counted6100%) was determined via blinded manner.
Caspase-3, -8, -9 activity. After 3 hours reperfusion, myo-
cardial tissue was homogenized in ice-cold lysis buffer for
30 seconds (PRO 200 homogenizer). Homogenates were centri-
fuged for 5 minutes at 10,000 g at 4uC. Supernatants were
collected, and protein concentrations were measured by BCA
method (Pierce Chemical, Rockford, IL). To each well of a 96-well
plate, supernatant containing 200 mg of protein was loaded and
incubated with 25 mg Ac-DEVD-pNA, Ac-IETC-pNA, or Ac-
LEHD-pNA at 37uC for 1.5 hours. pNA was cleaved from DEVD
(by caspase 3, BIOMOL), IETD (by caspase 8, BIOMOL), or
LEHD (by caspase 9, BIOMOL), and free pNA was quantified via
SpectraMax-Plus microplate spectrophotometer (Molecular De-
vices, Sunnyvale, CA) at 405 nm. Changes in caspase activity in I/
R tissue samples were calculated, and expressed as nmole pNA/
mg/h [26–28].
FADD siRNA knockdown and Immunoblotting in cell
H9C2 cells (ATCC) were cultured in DMEM (ATCC)
supplemented with 10% bovine calf serum and penicillin-
streptomycin in a humidified chamber with 5% CO2 at 37uC.
Rat FADD siRNA (Origene) transient transfections were con-
ducted by using 50 ng DNA and 3 ml HiPerfect Reagent (Qiagen)
per well in 24 well plates. Knockdown of FADD was confirmed by
qualitative RT-PCR using FADD specific primers (Intergrated
DNA Technologies). Real-Time quantification was performed by
sybr green (Biorad) using Biorad CFR96 detection system (Biorad).
Experiments were conducted on cells 48 hours after transfection.
Cells were treated with 10 mM chelerythrin for 30 min and
cleaved caspase-3 (CC-3) was blotted to evaluate cell death.
Cells were homogenized in ice-cold RIPA buffer (50 mMol/L
Tris-HCl, 135 mMol/L NaCl, 1% NP-40, 0.5% Sodium Deoxy-
cholate, 0.1% SDS, supplemented with 1 mMol/L PMSF, 10 mg/
ml Leupeptin, 20 mg/ml Aprotinin. The lysates were centrifuged
at 13,000 rpm for 30 minutes at 4uC and protein concentration
was determined using BCA Protein Assay (Pierce). Equal amounts
of protein were t electrophoresed through 4–20% polyacrylamide
gels and transferred to nitrocellulose membranes. Membranes
were blocked in Odyssey Blocking Buffer (Li-COR), and then
incubated with primary antibodies detecting CC-3 (Cell Signaling
Technologies) and GAPDH (Santa Cruz Biotechnology) at 4uC
overnight. Proteins were then detected using the Alexa Fluor
680 nm-coupled secondary antibodies (Life Technologies) using
the Odyssey Infrared Imaging System (Li-COR). Quantitative
densitometric analysis was performed using Odyssey infrared
imaging software (version 2.1).
Statistical analysis
All values in the text and figures are presented as mean 6 SEM
of n independent experiments. Statistical evaluation was per-
formed via one-way or two-way ANOVA followed by the
Bonferroni post-hoc test when appropriate. For paired compar-
ison, T-test was used and flowered with Welch’s correction. For
the survival study, Kaplan-Meier analysis was used. Probabilities
less than 0.05 were considered statistically significant.
Results
Genotyping and FADD expression pre- and post-I/R
Previous study from Zhang et al. showed that FADD:GFP exerts
similar function to FADD [19,29]. To detect the effects of FADD
upon post-ischemic heart failure, we first examined the expression
level of FADD among wild type C57/Bl6 (WT, FADD+/+),
FADD+/2FADD:GFP-MHC-Cre2, FADD2/2-FADD:GFP-
MHC-Cre2 (NLC) and FADD2/2-FADD:GFP-MHC-Cre+
(FADD knock out, FADD2/2) mouse lines as shown in
Figure 1A. Compared to WT (Figure 1A, lanes 1 and 2 from
the left), the level of FADD expression is significant higher in
FADD+/2FADD:GFP-MHC-Cre2 mice (lanes 3 and 4 from the
left) and similar to FADD2/2-FADD:GFP-MHC-Cre2 (NLC)
line (Lanes 5 and 6 from the left), but significantly lower in
FADD2/2-FADD:GFP MHC-Cre+ mice (Lanes 7 and 8 from the
left). There was no difference in FADD expression between WT
(FADD+/+) and FADD2/2-FADD:GFP-MHC-Cre2 (NLC) mice,
but about more than 50% reduction in FADD2/2 mice compared
to either WT or NLC mice in our whole heart tissue preparation.
Additionally, we examined the level of FADD expression up to 14
days post I/R in both NLC and FADD2/2 groups. Ischemia/
reperfusion injury increased FADD expression in both group
compared to pre-I/R condition as shown in Figure 1B. However,
the up-regulation of FADD was significantly less and delayed in
FADD2/2 group. Notice that there appears to be about a 3-fold
increase in FADD:GFP levels at 7 days post I/R FADD2/2 group
suggesting that there is an upregulation of FADD in the non-
myocyte cells including endothelial cells, smooth muscle cells, and
blood cells etc.
FADD deletion improves cardiac function in the acute I/R
phase
In the present study, two independent methods (echocardiog-
raphy and direct ventricular catheterization) were utilized to detect
potential differences in cardiac function between NLC and
FADD2/2 mice at 2 months of age. There were no differences
in body weight between NLC and FADD2/2 mice. Echocardi-
ography revealed no significant differences in LV ejection fraction
(EF%) and fractional shortening (FS%) between NLC and
FADD2/2 mice before myocardial ischemia (Figure 2). However,
EF% and FS% of FADD2/2 mice were significantly higher after
24 hours and 7 days reperfusion compared to those of NLC.
Direct ventricular hemodynamic measurements were consistent
with echocardiographic data. There were no significant differences
between the two groups in left ventricular systolic pressure (LVSP),
left ventricular end diastolic pressure (LVEDP), +dP/dt, and
2dP/dt before coronary occlusion. After 24 hours and 7 days
reperfusion, the values of LVEDP in FADD2/2 mice (10.6361.12
and 8.060.71, respectively) were significantly decreased compared
to NLC (14.6460.1 and 11.5760.97, respectively, P,0.015 and
0.001, Figure 3B). In addition, the values of 6dP/dt were
significantly greater than that of NLC (Figure 3B and C). Thus,
both echocardiographic and ventricular hemodynamic measure-
ments demonstrated FADD deletion attenuated cardiac dysfunc-
tion during the acute I/R phase.
FADD deletion attenuates cardiomyocyte death in the
acute I/R phase
The area of necrotic cardiac tissue (infarction) was expressed as
the percentage of the area-at-risk (AAR, Figure 4). There was no
significant difference between groups in the AAR expressed as the
percentage of the total left ventricle area, indicating comparable
degree of ischemic jeopardy in all I/R groups. After 30 minutes of
coronary occlusion and 24 hours reperfusion, the FADD2/2
group manifested 17% infarct, compared to 31% in the NLC
group as shown in Figure 4B. Consistently, FADD deletion
significantly reduced TUNEL-positive staining cells after 7 days of
FADD2/2 Protects against Heart Failure
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reperfusion (Figure 5A and B). These results provided direct
evidences that FADD deletion protected cardiomyocytes against
the I/R injury, and suggested the involvement of FADD in I/R-
induced myocardial apoptosis. Caspase-3, -8, and -9 are major
contributors to the progression of I/R-induced apoptosis. Caspase-
3 activation is the final common apoptotic pathway. To obtain
further evidences of the anti-apoptotic effect of FADD deletion,
caspase-3, -8, and -9 activities were determined in all groups. The
baseline of caspase-3, -8, and -9 are less than 100 nmole/mg/h in
our preparation in both NLC and FADD2/2 mice line. Upon the
I/R challenger, all caspase-3, -8 and -9 were increased in both
NLC and FADD2/2 groups. However, FADD knockout mark-
edly reduced caspase-3, -8, and -9 activities compared to NLC as
well (Figures 5 C).
FADD deletion augments cardiac function after long-
term myocardial ischemia
The above results suggest FADD deletion protects cardiomy-
ocytes, and augments cardiac function in the acute I/R phase. We
next tested a model of permanent ischemia, a six-week period of
myocardial ischemia leading to post-ischemic heart failure. At
baseline, no significant differences existed between groups; after
ischemia, the FADD knockout group (FADD2/2) manifested
augmented EF% and FS% via echocardiography compared to
NLC after 2, 4, and 6 weeks of ischemia (Figure 6A–C). These results
were confirmed with ventricular catheterization hemodynamic
analysis (Figure 6D–G). Taken together, these data suggest that
FADD deletion inhibits development of post-ischemic heart failure.
FADD deletion attenuates long-term myocardial
ischemia induced myocardial death and remodeling
TTC staining (as described above) was utilized to determine
long-term myocardial ischemia-induced cardiomyocyte death.
After 6 weeks of coronary occlusion, the FADD2/2 group
manifested 26.8364.17% infarct, compared to 41.2063.90% in
the NLC group. A representative photograph is presented in
Figure 7A, and yellow arrows point to the suture knots where the
coronary artery blood flow was interrupted. The results demon-
strated that, even with similar level of myocardial ischemia, infarct
size in FADD2/2 group was significantly smaller than in the NLC
group. In addition, after 8 weeks of coronary occlusion, hearts
underwent significant remodeling by increasing LV volume and
size in both groups; however, the remodeling was significantly less
in FADD2/2 group compared to NLC control mice (Figure 7C
and D). The ratio of heart length/tibia length (HL/TL) was about
0.5 in both sham groups, and 1.05360.31 and 0.7760.13 in the
NLC or FADD2/2 MI groups, respectively (Figure 7E). Consis-
tent with those results, FADD2/2 group had a better survival rates
compared to NLC control (Figure 7F). Taken together, these data
supports the fact that FADD deletion attenuates cardiac death in
permanent coronary occlusion (long-term ischemia) model.
FADD knockdown attenuates chelerythrin-induced
apoptosis in cell
To confirm the critical role of FADD mediated cell death we
knockdown FADD in H92C cell via the siRNA transfection
method as we previously described [30]. Treating the cell with
Figure 1. Time course of FADD expression in each group post-myocardial ischemia/reperfusion (I/R). (A) Top: Representative
photomicrographs of FADD expression in cardiac tissue by western blot in WT C57/BL6 (lanes 1–2) and FADD+/2-FADD:GFP-MHC-Cre2 (lanes 3–4)
control mice, FADD2/2-FADD:GFP-MHC-Cre2 (NLC, line 5–6) and FADD2/2-FADD:GFP-MHC-Cre+ (FADD2/2, line 7–8) mice. Bottom: Ratio of FADD
expression (FADD or FADD+FADD:GFP to GAPDH). (B) Top: Representative photomicrographs of FADD:GFP expression in cardiac tissue pre- and post-
MI/R by western blot in FADD2/2-FADD:GFP-MHC-Cre2 (NLC) and FADD2/2-FADD:GFP-MHC-Cre+ (FADD2/2) groups. Bottom: Ratio of FADD
expression (FADD:GFP to GAPDH). n = 4. **P,0.01 vs. FADD2/2-FADD:GFP-MHC-Cre2 (NLC). #P,0.05 vs pre-I/R condition in NLC and FADD2/2
groups respectively, n = 4.
doi:10.1371/journal.pone.0073537.g001
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Figure 2. Effect of FADD2/2 upon cardiac function as determined by echocardiography. (A) Representative echocardiographic recordings
pre- and post-24 hours and 7 days of reperfusion. (B) and (C) Graphic summary of LV ejection fraction (LVEF) and LV fractional shortening (LVFS) in
groups (n = 10–14 mice/group). *P,0.05, **P,0.01 FADD2/2 vs. NLC control (FADD:GFP MHC-Cre2).
doi:10.1371/journal.pone.0073537.g002
Figure 3. Effect of FADD2/2 upon cardiac function as determined by ventricular catheterization, spanning pre- to 7 days post-
reperfusion. (A) Left ventricular systolic pressure (LVSP). (B) Left ventricular end diastolic pressure (LVEDP). (C) Rate of rise of left ventricular pressure
(+dP/dt) and (D) Rate of reduction of left ventricular pressure (2dP/dt). n = 10–14 mice/group. *P,0.05 FADD2/2 vs. NLC control.
doi:10.1371/journal.pone.0073537.g003
FADD2/2 Protects against Heart Failure
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siRNA significantly decreased FADD expression by real time PCR
as show in Figure 8 A and B. There was no difference in 18 s
expression indicating the specific knockdown to FADD (Figure 8A).
As we expected, challenge the cell with chelerythrin significantly
reduced CC-3 expression in FADD siRNA treated cell group
(Figure 8 C and D) indicating the amelioration of apoptosis with
FADD knockdown.
Discussion
The present study makes several novel discoveries. Firstly,
FADD deletion inhibited cardiomyocyte apoptosis following acute
I/R. The anti-apoptotic effects of FADD deletion were mediated
not only by the death receptor pathway, but also the mitochon-
drial pathway (as demonstrated by the reduced caspase-9 activity).
Secondly, FADD deletion improved cardiac function after I/R.
Finally, and most importantly, FADD deletion attenuated long
term-ischemia induced cell death, and delayed post-ischemic heart
failure progression. Although the anti-apoptotic effects of FADD
inhibition have been recognized for more than a decade, to our
knowledge, this is the first study demonstrating genetic manipu-
lation of FADD for successful amelioration of post-ischemic heart
failure.
The earliest gene therapies involving FADD centered on anti-
tumor and immunomodulative therapies. Kondo et al. investigated
the effect of FADD overexpression in malignant glioma progres-
sion, revealing that regardless of Fas/APO-1 expression levels,
FADD gene overexpression significantly inhibited both in vitro and
in vivo survival of malignant glioma cells via apoptosis induction
[31]. In another study, Kobayashi et al. eliminated synoviocytes via
injection of local FADD-expressing adenovirus (Ad-FADD),
Figure 4. FADD2/2 ameliorates post-I/R myocardial infarct size.
(A) Representative photograph of TTC stained heart tissue section
obtained 24 hours I/R in FADD2/2 and NLC groups. (B) Graphic summery
of infarct size expressed as percentage of area-at-risk (AAR) and the size
of AAR. n = 8–10 mice/group. **P,0.01, FADD2/2 vs. NLC control.
doi:10.1371/journal.pone.0073537.g004
Figure 5. Effect of FADD2/2 reduced post-I/R cardiomyocyte apoptosis. (A) Representative photomicrographs of in situ detection of cardiac
tissue DNA fragments from mice subjected to 30 minutes of ischemia and 3 hours or 7 days of reperfusion. Tissue sections were stained with DAPI
(blue), anti-actinin (red) and TUNEL (green). TUNEL-positive nuclei were summarized in graph (B) and expressed as percentage of all tissues subject to
I/R staining TUNEL-positive. (C) Caspase-3, -8, and -9 activity in ischemic cardiac tissue after 3 hours reperfusion. n = 10–12 animals/group. *P,0.05,
**P,0.01 vs. NLC control.
doi:10.1371/journal.pone.0073537.g005
FADD2/2 Protects against Heart Failure
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inducing apoptosis of rheumatoid synovium, demonstrating the
clinical possibilities of FADD manipulation [32,33]. FADD has
therefore been an attractive possible gene therapy target in the
treatment of various diseases involving apoptotic mechanisms,
including oncologic, autoimmune, and possibly cardiovascular
pathologies. In the present study, we utilized cardiac-specific
FADD2/2 mice and demonstrated that FADD deletion improved
post-ischemic cardiac function and alleviated post-ischemia
cardiomyocytes apoptosis. This anti-apoptotic effect of FADD
deletion was further confirmed in FADD siRNA infected cell
study. Furthermore, in a permanent ischemia model, FADD
deletion postponed post-ischemic heart failure phenotype devel-
opment and improved survival.
Existing evidence strongly suggests an important pathophysio-
logical role for the death receptor apoptotic pathway in heart
failure pathogenesis. The best-characterized death receptors are
Fas (also termed CD95 or Apo1) and tumor necrosis factor
receptor 1 (TNFR1). Ferrari et al. and Testa demonstrated patients
with end-stage congestive heart failure harbored elevated circu-
lating levels of TNF-a (ligand for TNFR1) and studies suggest a
direct relationship between serum TNF-a levels and heart failure
severity [34,35]. Additionally, both Fas and FasL expression were
increased in hypoxic myocytes, and Fas pathway activation has
been shown to induce cardiomyocyte apoptosis [36,37]. Consistent
with these reports, our study supports that FADD expression is
increased dramatically in ischemic heart tissue. However, in
FADD2/2 mice, the post ischemia induced up regulation of
FADD was inhibited to a much less degree. Previous studies and
our results support the activation of the death receptors pathway
after ischemia/reperfusion, evidenced by activated FADD expres-
sion. The direct result of activated FADD is apoptosis mediated by
increased caspase-8 activity and downstream caspase-3 activity
[14]. FADD deletion attenuates cardiomyocyte death and
improves cardiac function, ultimately protecting the ischemic
heart from heart failure.
We demonstrated that FADD2/2 decreased not only caspase-3
and -8 activities, but also caspase-9 activity. Several studies
investigating cross talk between the apoptotic pathways explain
this phenomenon. Date et al. demonstrated that FasL overex-
pression activated both caspase-8 and -9 in neonatal cardiomy-
ocytes [38]. Recently, receptor-interacting protein kinases-1
(RIPK1) and RIPK3 as a lethal defect in caspase-8-, FADD-,
and FLIP-deficient animals and tissues has been reported [39].
The RIPKs are known as killers, being responsible for a
nonapoptotic form of cell death with features similar to necrosis
[40]. The present study did not investigate the underlying
mechanisms of FADD2/2 mediated cardioprotection and
possible role in necrosis pathway. However, our caspase activity
results suggest FADD deletion mediate anti-apoptosis may
through dual apoptotic pathways.
Figure 6. Effect of FADD2/2 on cardiac function after 6 weeks MI. (A) Representative photomicrographs of echocardiographic measurements
in each group over 6 weeks MI. Linear chart depicts change of LVEF (B) and LVFS (C) after 6 weeks ischemia. n = 8 animals in each group. *P,0.05,
**P,0.01 vs NLC (Two way ANOVA). (D–G) Hemodynamic measurements of cardiac function at 6 week post-MI or Sham in NLC and FADD2/2 groups.
(D) LVSP, (E) LVEDP, (F) +dP/dt and (D) 2dP/dt. n = 5–8 animals in each group. *P,0.05, **P,0.01 FADD2/2 vs. NLC control.
doi:10.1371/journal.pone.0073537.g006
FADD2/2 Protects against Heart Failure
PLOS ONE | www.plosone.org 7 September 2013 | Volume 8 | Issue 9 | e73537
Figure 7. Effect of FADD2/2 on cardiac infarct size, cardiac remodeling and survival after 6 weeks MI. (A) representative TTC stained
heart tissue section at 6 week post-MI in FADD2/2 and NLC control groups. (B) Graphic summary of infarct size expressed as the length of the scare/
LV circumference, n = 8 animals in each group. (C) Graphic presentation of LV area in NLC and FADD2/2 groups, P,0.05 FADD2/2 vs. NLC, n = 8 in
each groups. (D) Graphic presentation of LVIDd measured by echocardiography. P,0.05 FADD2/2 vs. NLC, n = 8 in each groups. (E) Graphic
presentation the ratio of heart length (HL)/tibia length (TL) in sham or MI mice. P,0.05 FADD2/2 vs. NLC, n = 8 in each groups. (F) Survival curve in 8
week post-sham (n= 8 in each group) or post-MI mice (n = 23 in each group). *P,0.05, FADD2/2 vs. NLC control.
doi:10.1371/journal.pone.0073537.g007
Figure 8. Knockdown FNDD in cell reduces chelerythrin-induced apoptosis. (A) Representative real time PCR tracings of transcript for 18S
and FADD in H9C2 cells. Black: control, green: scramble siRNA, and red: FADD siRNA. (B) Quantification of relative mRNA expression of FADD in FADD
specific siRNA or scrambled siRNA transfected H9C2 cells compared to control, *P,0.05, t test, n = 4 per group. (C) Representative Western blot
showing the release of cleaved caspase-3 (CC-3) in H9C2 cells treated with chelerythrin. (D) Quantification of CC-3 release in FADD specific siRNA or
scrambled siRNA transfected H9C2 cells compared to that of control cells, *P,0.05, ANOVA, n= 4 per group.
doi:10.1371/journal.pone.0073537.g008
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Limitations
As gene therapy technology develops, identification of ideal
targets ameliorating disease represents a huge challenge in the
biomedical field. The current study determined whether FADD
could be a therapeutic target alleviating progression of post-
ischemic heart failure. Future research investigating the specific
mechanisms (e.g. effects upon MAPK, Bcl-2, or relationship
between FADD knockout and RIPK1 linked necrosis etc.)
underlying the cardioprotective effects of FADD deletion against
post-ischemic heart failure is warranted.
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